Playback speed
10 seconds
ESMO 2022 on the Randomized Phase 3 FORWARD I Study: Analyses of Patient-Reported Outcomes With Mirvetuximab Soravtansine vs. Standard Chemo in Ovarian Cancer
By
ESMO 2022 Conference Coverage
FEATURING
Kathleen Moore
By
ESMO 2022 Conference Coverage
FEATURING
Kathleen Moore
653 views
September 27, 2022
Login to view comments.
Click here to Login